Analyzing FDA Draft Guidance On Clinical Trial Diversity
On June 26, the U.S. Food and Drug Administration released draft guidance on clinical trial diversity action plans, outlining new required elements of drug and device submissions, updating recommendations for sponsors,...To view the full article, register now.
Already a subscriber? Click here to view full article